Medical Condition News

RSS

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

21 Jan 2011

COPD patients on LTOT may face high risk of death from cardiovascular disease

Patients suffering from chronic obstructive pulmonary disease who are on long-term oxygen therapy have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD patients on LTOT today face an increased risk of death from cardiovascular disease and other non-respiratory ailments.

20 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Preliminary top-line results from levomilnacipran Phase III study for MDD

Forest Laboratories, and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of major depressive disorder.

20 Jan 2011

Semen allergy to one's own

According to a study from Dutch researchers, some men are allergic to their own semen, developing a mysterious flu-like illness after they have an ejaculation. The condition, known as post-orgasmic illness syndrome or POIS, has been documented since 2002. It manifests as feverishness, runny nose, extreme fatigue and burning eyes, which can last for up to a week.

20 Jan 2011

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

Genzyme Corp. today announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term growth of Myozyme® and Lumizyme® for Pompe disease.

20 Jan 2011

Archimedes, FDA collaborate to develop computer model of clinical trials evaluating weight loss medications

Archimedes Inc., a healthcare modeling company, announced today that it has entered into a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) to develop a computer model of clinical trials evaluating weight loss medications. The model will be used to obtain a better understanding of the benefits of weight loss against the long-term risks of cardiovascular outcomes in patients treated with weight loss drugs.

20 Jan 2011

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

DiagnoCure Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering lab services, today announced positive initial results of a multi-center clinical study of 241 stage II colon cancer patients, a population categorized as low risk by traditional methods yet with an average recurrence rate of 20%.

20 Jan 2011

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Volcano Corporation today announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care-- angiographic imaging-- alone.

20 Jan 2011

Genetic expression can be modified with natural substances to prevent chronic illness

Research findings demonstrating how genetic expression can be modified with natural substances to prevent chronic illness was the topic of an address by Jeffrey Bland, Ph.D., FACN, FACB, at the 8th Annual Scripps Center for Integrative Medicine 2011 conference in San Diego, California, January 13 - 16.

20 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

American Lung Association releases 2010 State of Tobacco Control Report

The American Lung Association released its State of Tobacco Control 2010 report today, which tracks progress on key tobacco control policies at the federal and state level, assigning grades based on whether laws are adequately protecting citizens from the enormous burden caused by tobacco use.

20 Jan 2011

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

ACD CPR performed with combination of ResQPump and ResQPOD could save lives of cardiac arrest patients

A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in today's online edition of The Lancet.

20 Jan 2011

Neuros Medical announces initial feasibility study results of HFAC Nerve Block technology

Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.

20 Jan 2011

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Significant portion of U.S. population does not have access to trauma care

A significant portion of the U.S. population does not have access to trauma care within an hours' drive, with certain vulnerable groups at higher risk of worse access, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals.

20 Jan 2011

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE.

20 Jan 2011

Medical Condition News

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

COPD patients on LTOT may face high risk of death from cardiovascular disease

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Alliqua completes transdermal pain patch initial study for treatment of PHN

Preliminary top-line results from levomilnacipran Phase III study for MDD

Semen allergy to one's own

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

Archimedes, FDA collaborate to develop computer model of clinical trials evaluating weight loss medications

Study demonstrates prognostic value of DiagnoCure's Previstage GCC Colorectal Cancer Staging Test

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Genetic expression can be modified with natural substances to prevent chronic illness

Cognition Therapeutics closes $2.5 million Series A1 financing

American Lung Association releases 2010 State of Tobacco Control Report

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

ACD CPR performed with combination of ResQPump and ResQPOD could save lives of cardiac arrest patients

Neuros Medical announces initial feasibility study results of HFAC Nerve Block technology

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

Significant portion of U.S. population does not have access to trauma care

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News